Press Releases

Press Releases

View all news
Voronoi Files Phase 1 IND Application for HER2-Positive Solid Tumor Therapy VRN10
2024.11.29
Voronoi disclosed on the 29th that it has submitted a Phase 1 IND application (clinical trial authorization application) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VRN10 in patients with HER2-positive and HER2-mutant solid tumors.
The Phase 1 clinical trial of VRN10 will be conducted in approximately 70 patients with solid tumors, including HER2-positive breast cancer, at 5 sites in Korea and Australia.
In addition to safety, including adverse events in patients, the Phase 1 trial will also evaluate efficacy endpoints such as objective response rate (ORR), progression-free survival (PFS), and intracranial response rate. In particular, once a pharmacologically active dose is reached in the dose-escalation study, the company plans to enroll additional patients (backfill) in about three cohorts to observe tolerability and efficacy more closely.
Meanwhile, with the approval of Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate (ADC) targeting HER2-positive breast and gastric cancer, many patients in Korea and abroad are being treated with Enhertu, and since there is still no clear treatment for Enhertu-resistant cancers, the unmet medical need is growing. At the ENA international conference last October, Voronoi presented non-clinical results confirming that VRN10 also has high activity against Enhertu-resistant breast cancer cells. It also showed that improving selectivity for HER2 over EGFR could reduce side effects such as diarrhea and dermatitis, and revealed that its brain penetrance is far superior to that of existing therapies. In addition, as an irreversible HER2-targeting TKI, VRN10 promotes the cellular uptake of HER2 ADCs such as Enhertu, suggesting that synergy can be expected when used in combination with HER2 ADCs.
According to a Voronoi representative, based on its excellent preclinical data, VRN10 is a drug expected to show efficacy across a variety of cancer types, including HER2-positive breast cancer patients with brain metastases, where an unmet medical need exists. Daekwon Kim, CEO of the Research Division of Voronoi, said, "VRN10 not only has high selectivity for HER2 but also has potent activity against Enhertu-resistant HER2 solid tumors, so we expect it can be developed as a new treatment option for patients. We hope that the clinical success of VRN10 will bring new hope to patients with HER2-positive solid tumors and their families."